MetLife Investment Management’s iRadimed IRMD Stock Holding History

MetLife Investment Management’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$429K	Sell	4,458 -275	-6%	-$27.5K	﹤0.01%	1829
2025 Q4	$460K	Hold	4,733	–	–	﹤0.01%	1830
2025 Q3	$337K	Hold	4,733	–	–	﹤0.01%	2018
2025 Q2	$283K	Hold	4,733	–	–	﹤0.01%	1990
2025 Q1	$248K	Sell	4,733 -112	-2%	-$6.29K	﹤0.01%	2082
2024 Q4	$266K	Buy	4,845 +494	+11%	+$26K	﹤0.01%	2150
2024 Q3	$219K	Hold	4,351	–	–	﹤0.01%	2242
2024 Q2	$191K	Buy	4,351 +465	+12%	+$19.8K	﹤0.01%	2271
2024 Q1	$171K	Hold	3,886	–	–	﹤0.01%	2279
2023 Q4	$184K	Hold	3,886	–	–	﹤0.01%	2283
2023 Q3	$172K	Hold	3,886	–	–	﹤0.01%	2293
2023 Q2	$186K	Hold	3,886	–	–	﹤0.01%	2326
2023 Q1	$153K	Hold	3,886	–	–	﹤0.01%	2373
2022 Q4	$110K	Hold	3,886	–	–	﹤0.01%	2558
2022 Q3	$117K	Hold	3,886	–	–	﹤0.01%	2598
2022 Q2	$132K	Hold	3,886	–	–	﹤0.01%	2573
2022 Q1	$174K	Buy	3,886 +1,395	+56%	+$64.5K	﹤0.01%	2440
2021 Q4	$115K	Buy	+2,491	New	+$100K	﹤0.01%	2361

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's IRMD Position: Q1 2026 in Review

MetLife Investment Management reduced its iRadimed (IRMD) stake by 5.8% in Q1 2026, selling an estimated $27.5K and leaving 4,458 shares worth $429K. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

MetLife Investment Management first reported a position in IRMD in Q4 2021 and has held it in 18 quarters since. The position peaked at $460K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

MetLife Investment Management held 4,458 shares of iRadimed worth $429K as of Q1 2026.
MetLife Investment Management sold 275 iRadimed shares in Q1 2026, an estimated $27.5K.
iRadimed made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1829 holding.
MetLife Investment Management first reported a position in iRadimed in Q4 2021 and has held it in 18 quarters since.
MetLife Investment Management's iRadimed position peaked at $460K in Q4 2025.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.